Hypoxic pulmonary hypertension in man: what minimum daily duration of hypoxaemia is required?

Weitzenblum E., Chaouat A.

Source: Eur Respir J 2001; 18: 251-253
Journal Issue: August

PDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Weitzenblum E., Chaouat A.. Hypoxic pulmonary hypertension in man: what minimum daily duration of hypoxaemia is required?. Eur Respir J 2001; 18: 251-253

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016

The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016

Hypoxic pulmonary vasoconstriction in COPD-associated pulmonary hypertension: been there, done that?
Source: Eur Respir J, 50 (1) 1701191; 10.1183/13993003.01191-2017
Year: 2017



Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients
Source: Eur Respir J 2004; 24 : 580-586
Year: 2004



Comparing cardiopulmonary responses to incremental exercise in patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension
Source: Annual Congress 2011 - Altered mechanisms during exercise in disease
Year: 2011


Impact of cyanosis on ventilatory kinetics during stairclimbing in pulmonary arterial hypertension
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021


Riociguat improves excessive exercise ventilation in patients with inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Year: 2013


Duration of treatment in acute pulmonary embolism: time for a change?
Source: International Congress 2017 – Open questions in pulmonary vascular diseases
Year: 2017


Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016


Recovery from dynamic exercise dissociates ventilatory from pulmonary gas exchange responses in patients with chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2013 –Mechanisms contributing to exercise limitation in health and respiratory, cardiac and pulmonary vascular diseases
Year: 2013

Long-term improvement of pulmonary haemodynamics and exercise capacity in patients with pulmonary hypertension and hypoventilation following NIPPV and influence of NIPPV adherence
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015

Pulmonary embolism and pulmonary hypertension - is our follow up adequate?
Source: Eur Respir J 2005; 26: Suppl. 49, 270s
Year: 2005

Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015

Does sildenafil improves exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009


Evaluation of criteria for exercise-induced pulmonary hypertension in patients with resting pulmonary hypertension
Source: Eur Respir J, 50 (3) 1700784; 10.1183/13993003.00784-2017
Year: 2017



Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history
Source: Eur Respir Rev 2009; 18: 170-173
Year: 2009



Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015

Beta-blocker therapy nor hyperoxic breathing lowers ventilatory drive in pulmonary arterial hypertension patients
Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange
Year: 2014


Inflammation in pulmonary arterial hypertension: is it time to quell the fire?
Source: Eur Respir J 2014; 43: 685-688
Year: 2014